Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Phrixus Pharmaceuticals Inc
Profile last edited on: 6/18/21      CAGE: 4GMB4      UEI:

Business Identifier: Duchenne muscular dystrophy (DMD) and heart failure therapies
Year Founded
2006
First Award
2007
Latest Award
2012
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1600 Huron Parkway Building 520 2nd Floor
Ann Arbor, MI 48109
Location: Single
Congr. District: 12
County: Washtenaw

Public Profile

Phrixus Pharmaceuticals, Inc. develops and commercializes pharmaceuticals and therapies related to Duchenne Muscular Dystrophy and acute heart failure. The company has developed Carmeseal, a therapy for the treatment of heart failure. There have been two in vivo efficacy studies conducted by Phrixus for muscular dystrophy and two conducted for heart failure.

Extent of SBIR involvement

User Avatar
Phase I Awards
6
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$2,385,027
Phase II Dollars
$0
Total Awarded
$2,385,027

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2012 1 NIH $622,877
Project Title: Treatment of Muscular Dystrophy-Associated Dilated Cardiomyopathy with P-188
2011 1 NIH $583,225
Project Title: Effects of P-188 on Respiratory Function and Diaphragm Degeneration in the MDX MO
2010 1 NIH $306,708
Project Title: Poloxamer 188 Mechanism of Action in Ischemic Heart Failure.
2009 1 NIH $379,487
Project Title: Development of Poloxamer-188 for the Treatment of Muscular Dystrophy Associated H
2008 1 NIH $277,646
Project Title: Poloxamer-188 for the prevention of fibrosis during peritoneal dialysis

Key People / Management

  Thomas A Collet -- President, CEO, and Co-founder

  Gerald Brennan -- Executive Officer and DireCTOr

  Bruce E Markham -- Chief Scientific Officer, VP R&D, and Co-founder

  James Symons -- Acting VP Clinical and Regulatory Affairs

Company News

There are no news available.